ArticleNature medicine2018
Biochemical autoregulatory gene therapy for focal epilepsy.
Article in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 69 citations in OpenAlex.
- Neuron-derived neurotrophic factor-positive interneurons: a cellular target for anti-seizure therapies.EBioMedicine · 2026Article
- Uncovering the Key Circuit FOSL2/FOS/EGR3/EGR1, Contributing to the Hyperexcitability of Excitatory Neurons in the Epileptic Temporal Cortex and Hippocampus.International journal of molecular sciences · 2026Article
- A bioluminescent activity dependent platform, BLADe, for converting intracellular activity to photoreceptor activation.Scientific reports · 2026Article
- Upregulation of CCK3R leading to the suppression of chronic seizures.Translational psychiatry · 2025Article
- State-of-the-art gene therapy in epilepsy.Current opinion in neurology · 2025Review
- Chemogenetics with PSAMGene therapy · 2025Article
- International Precision Child Health Partnership (IPCHiP): an initiative to accelerate discovery and improve outcomes in rare pediatric disease.NPJ genomic medicine · 2025Review
- Review
- Suppression of epileptic seizures by transcranial activation of KNature communications · 2025Article
- Recent advances and current status of gene therapy for epilepsy.World journal of pediatrics : WJP · 2024Review
- Gene therapy for epilepsy targeting neuropeptide Y and its Y2 receptor to dentate gyrus granule cells.EMBO reports · 2024Article
- Chemogenetic Tools and their Use in Studies of Neuropsychiatric Disorders.Physiological research · 2024Review
- A pH-sensitive closed-loop nanomachine to control hyperexcitability at the single neuron level.Nature communications · 2024Article
- Characterization of the intrahippocampal kainic acid model in female mice with a special focus on seizure suppression by antiseizure medications.Experimental neurology · 2024Article
- Acetylcholine receptor based chemogenetics engineered for neuronal inhibition and seizure control assessed in mice.Nature communications · 2024Article
- Epilepsy insights revealed by intravital functional optical imaging.Frontiers in neurology · 2024Review
- Advancement in CRISPR/Cas9 Technology to Better Understand and Treat Neurological Disorders.Cellular and molecular neurobiology · 2023Review
- 'On-demand' gene therapy for epilepsy.Nature reviews. Neurology · 2023Article
- Design and engineering of genetically encoded protein biosensors for small molecules.Current opinion in biotechnology · 2022Review
- On-demand cell-autonomous gene therapy for brain circuit disorders.Science (New York, N.Y.) · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Despite the introduction of more than one dozen new antiepileptic drugs in the past 20 years, approximately one-third of people who develop epilepsy continue to have seizures on mono- or polytherapy
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.